Page last updated: 2024-12-04

4-aminobenzoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-Aminobenzoic Acid: An aminobenzoic acid isomer that combines with pteridine and GLUTAMIC ACID to form FOLIC ACID. The fact that 4-aminobenzoic acid absorbs light throughout the UVB range has also resulted in its use as an ingredient in SUNSCREENS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-ammoniobenzoate : A zwitterion obtained by transfer of a proton from the carboxy to the amino group of 4-aminobenzoic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

4-aminobenzoic acid : An aminobenzoic acid in which the amino group is para to the carboxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID978
CHEMBL ID542
CHEBI ID30753
CHEBI ID194474
SCHEMBL ID8249
SCHEMBL ID13232108
MeSH IDM0015714
PubMed CID4876
CHEMBL ID1762658
CHEBI ID17836
MeSH IDM0015714

Synonyms (223)

Synonym
smr000471833
MLS001066325
BIDD:ER0375
paranate
anti-chromotrichia factor
pabafilm
aminobenzoic acid, para
bacterial vitamin h1
vitamin bx
vitamin h'
chromotrichia factor
paraminol
benzoic acid, 4-amino-
pabacyd
4-carboxyaniline
pabamine
p-carboxyphenylamine
PAB ,
p-carboxyaniline
nsc7627
super shade by coppertone
trichochromogenic factor
anticanitic vitamin
.gamma.-aminobenzoic acid
hachemina
pabanol
amben
benzoic acid, p-amino-
1-amino-4-carboxybenzene
nsc-7627
aminobenzoic acid
4-carboxyphenylamine
4-aminobenzoesaeure
gamma-aminobenzoic acid
CHEBI:30753 ,
p-aminobenzoesaeure
KBIO1_000783
DIVK1C_000783
NCI60_041683
4-aminobenzoic acid, reagentplus(r), 99%
SPECTRUM_000036
OPREA1_221096
IDI1_000783
BSPBIO_001828
SPECTRUM5_000778
MLS001335920
MLS001335919
4-amino-benzoic acid
inchi=1/c7h7no2/c8-6-3-1-5(2-4-6)7(9)10/h1-4h,8h2,(h,9,10
sunbrella
rvpaba lipstick
papacidum
rvpaba
acidum paraminobenzoicum
potaba
romavit
NCGC00091051-01
brn 0471605
epa pesticide chemical code 233300
ccris 6209
acido p-aminobenzoico [italian]
hsdb 6840
nsc 7627
caswell no. 033b
ai3-02436
kyselina p-aminobenzoova [czech]
einecs 205-753-0
benzoic acid, 4-amino
P-AMINO-BENZOATE ,
abee
para-aminobenzoate
4-aminobenzoic acid
para-aminobenzoic acid
C00568
paba
150-13-0
p-aminobenzoic acid
4-aminobenzoic acid, purified by sublimation, >=99%
4-aminobenzoic acid, reagentplus(r), >=99%
DB02362
rvpaba lipstick (tn)
D02456
aminobenzoic acid (usp)
KBIO2_002964
KBIO3_001328
KBIOSS_000396
KBIO2_005532
KBIOGR_000584
KBIO2_000396
SPECTRUM4_000142
SPECTRUM2_000123
SPECTRUM3_000294
NINDS_000783
SPBIO_000166
STK397441
4A5E7DD8-8A22-4642-86BF-05B778C0C78E
A0269
bdbm50145829
BMSE000066
CHEMBL542 ,
CHEBI:194474
4-ammoniobenzoate
4-azaniumylbenzoate
4-aminobenzoic acid zwitterion
AKOS000118983
A809010
NCGC00091051-03
NCGC00091051-02
amino benzoic acid
BMSE000887
unii-tl2tje8qtx
ec 205-753-0
kyselina p-aminobenzoova
tl2tje8qtx ,
aminobenzoic acid [usp]
acido p-aminobenzoico
NCGC00259251-01
tox21_201702
tox21_300087
NCGC00253923-01
pabagel
BMSE000916
cas-150-13-0
tox21_111069
dtxsid6024466 ,
dtxcid404466
HMS2269E10
aminobenzoate
S4510
FT-0617557
vitamin h1
EPITOPE ID:115017
para-aminobenzoic acid [vandf]
aminobenzoic acid [usp monograph]
aminobenzoic acid [usp-rs]
procaine benzylpenicillin impurity a [ep impurity]
4-aminobenzoic acid [hsdb]
4-aminobenzoic acid [ep impurity]
aminobenzoic acid [who-dd]
para-aminobenzoic acid [iarc]
aminobenzoic acid [mart.]
p-aminobenzoic acid [mi]
4-aminobenzoic acid [ep monograph]
tetracaine hydrochloride impurity a [ep impurity]
paba [inci]
p-aminobezoic acid
p-amino benzoic acid
4-(amino)benzoic acid
4-aminobenzoic-acid
p-carboxy aniline
4-aminobezoic acid
p-amino-benzoic acid
4-amino benzoic acid
SCHEMBL8249
tox21_111069_1
NCGC00091051-04
CS-4505
SCHEMBL13232108
AM86626
Q-200432
aniline-4-carboxylic acid
anticantic vitamin
component of presun (salt/mix)
aminobenzoic acid, pharmaceutical secondary standard; certified reference material
HY-B1008
mfcd00007894
F2191-0259
AC-8107
4-aminobenzoic acid, analytical standard
4-aminobenzoic acid, >=98.0% (hplc/nt)
4-aminobenzoic acid, saj special grade, 99.5-100.2%
aminobenzoic acid, united states pharmacopeia (usp) reference standard
4-aminobenzoic acid, 98.5-100.2%, saj first grade
Z57127446
4-aminobenzoic acid, 99%
4-aminobenzoic acid, european pharmacopoeia (ep) reference standard
4-aminobenzoic acid, vetec(tm) reagent grade, 98%
SBI-0051277.P003
actipol
antichromotrichia factor
aniline-4-carboxylate
gamma-aminobenzoate
trochromogenic factor
SY003749
potassium-p-aminobenzoate
Q284959
p-aminobenzoic acid,(s)
AS-12493
EN300-17988
p-aminobenzoic acid 100g
HMS3870E13
CCG-266139
p-aminobenzoic acid, free acid
benzoic-2,3,5,6-d4acid, 4-amino-
BP-31227
AKOS005449626
4-aminobenzoic acid, ion(1-)
CHEBI:17836
2906-28-7
bacterial vitamin h
trichromogenic factor
papacidium
NCGC00178975-01
4-aminobenzoic acid-ion(1-)
benzoic acid-p-amino-ion(1-)
4-aminobenzoate ion
benzoic acid, 4-amino-, ion(1-)
p-aminobenzoic acid anion
p-aminobenzoate anion
4-aminobenzoate
p-aminobenzoate
STK379527
CHEMBL1762658 ,
bdbm50340076
para-aminobenzoates
3Q2A
4-aminophenylcarboxylate
ALYNCZNDIQEVRV-UHFFFAOYSA-M
AB00053416_08
DTXSID40183306
Q27102654
4-aminophenyl formate? (sorafenib impurity pound(c)
CS-0164204

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Toxic effects of procaine were, therefore, concluded to be due to the accumulation of the drug in the brain."( Effect of pretreatment with tricresylphosphates and phenobarbital on the metabolism and toxicity of procaine in rats.
Moroi, K; Satoh, T, 1977
)
0.26
" In this article, the toxic effect of CsA on pancreatic islet cells and the preventive effect of K-MAP on CsA-associated islet cell toxicity were investigated."( Modulation of prostaglandin metabolism by K-MAP and prevention of toxic effect of cyclosporin on pancreatic islet cells.
Babazono, T; Fuchinoue, S; Fujikawa, H; Fujita, S; Hayashi, T; Honda, H; Kawai, T; Nakagawa, Y; Nakajima, I; Teraoka, S, 1989
)
0.28
"Age-related changes in the expression of xenobiotic biotransformation enzymes can result in differences in the rates of chemical activation and detoxification, affecting responses to the therapeutic and/or toxic effects of chemicals."( Neonatal ontogeny of murine arylamine N-acetyltransferases: implications for arylamine genotoxicity.
Chau, B; McQueen, CA, 2003
)
0.32
" Exposition to sunlight, in fact, can cause sunscreen photodegradation and determine their decrease in UV protection often with the occurrence of allergic and/or toxic degradation products."( Anionic clays for sunscreen agent safe use: photoprotection, photostability and prevention of their skin penetration.
Ambrogi, V; Bertini, B; Latterini, L; Nocchetti, M; Perioli, L; Ricci, M; Rossi, C, 2006
)
0.33
" These results provide evidence that using the technology of zeolite encapsulation to prepare a supramolecular sunscreen that minimizes the skin contact of active ingredients may reduce the adverse effects of "naked" sunscreens on biological systems."( Protecting the protectors: reducing the biological toxicity of UV sunscreens by zeolite encapsulation.
Chrétien, MN; Migahed, L; Scaiano, JC,
)
0.13
" The similarity between sunburn and a phototoxic response has delayed recognition of this adverse effect until now."( Phototoxicity to a sunscreen ingredient. Padimate A.
Kaidbey, KH; Kligman, AM, 1978
)
0.26
" In this article, the toxic effect of CsA on pancreatic islet cells and the preventive effect of K-MAP on CsA-associated islet cell toxicity were investigated."( Modulation of prostaglandin metabolism by K-MAP and prevention of toxic effect of cyclosporin on pancreatic islet cells.
Babazono, T; Fuchinoue, S; Fujikawa, H; Fujita, S; Hayashi, T; Honda, H; Kawai, T; Nakagawa, Y; Nakajima, I; Teraoka, S, 1989
)
0.28
"BMS-962212 was well tolerated; there were no signs of bleeding, and adverse events were mild."( First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects.
Cirincione, B; DeSouza, M; Frost, CE; Frost, RJA; Knabb, RM; LaCreta, FP; Lee, J; Luettgen, JM; Ma, X; Mugnier, P; Perera, V; Russo, C; Seiffert, D; Ueno, T; Wang, Z; Yones, C; Zhao, Y, 2018
)
0.48
" CHF6001 was well tolerated with no relationship between dose and adverse events."( Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers.
Govoni, M; Lucci, G; Mariotti, F; Nandeuil, MA; Santoro, D,
)
0.13
" Catalase mildly reduced the toxic effect and carboxylesterase showed obvious ability to reverse the toxicity of DMABEE."( Cytotoxicity and genotoxicity of DMABEE, a co-photoinitiator of resin polymerization, on CHO-K1 cells: Role of redox and carboxylesterase.
Chang, HH; Chang, MC; Chen, YJ; Jeng, JH; Shih, WC; Tsai, YL; Wang, YL, 2020
)
0.56
"CHF6001 had no effect in the primary lung function analysis, although was well-tolerated with no gastrointestinal adverse event signal."( Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study.
Emirova, A; Francisco, C; Govoni, M; Nandeuil, MA; Santoro, D; Singh, D, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
"In rabbits and rats pharmacokinetic studies on the anti-fibrinolytics 4-aminomethylbenzoic acid (PAMBA), trans-4-aminomethylcyclohexane-1-carboxylic acid (AMCA), and epsilon-aminocaproic acid (EACA) were carried out using the tritium labelled compounds."( [Pharmacokinetic studies with 3H-labelled synthetic antifibrinolytics].
Klöcking, HP; Markwardt, F; Richter, M, 1982
)
0.26
" Development of BB2r-targeted agents, based on the bombesin (BBN) peptide, has largely involved the use of the bifunctional chelate approach in which the linking group serves several key roles including pharmacokinetic modification."( Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model.
Figueroa, SD; Garrison, JC; Hoffman, TJ; Naz, F; Rold, TL; Sieckman, GL; Sublett, SV; Volkert, WA, 2008
)
0.35
" pneumoniae, alveolar macrophage-independent clearance mechanisms were dominant, with a clearance half-life of 24 min compared to 135 min for alveolar macrophage-dependent clearance."( Importance of bacterial replication and alveolar macrophage-independent clearance mechanisms during early lung infection with Streptococcus pneumoniae.
Brown, JS; Callard, R; Camberlein, E; Chimalapati, S; Cohen, JM; Edwards, LA; Hyams, CJ; José, R; Marshall, H; Noursadeghi, M; van Rooijen, N; Yuste, J, 2015
)
0.42
"In rabbits and rats pharmacokinetic studies on the anti-fibrinolytics 4-aminomethylbenzoic acid (PAMBA), trans-4-aminomethylcyclohexane-1-carboxylic acid (AMCA), and epsilon-aminocaproic acid (EACA) were carried out using the tritium labelled compounds."( [Pharmacokinetic studies with 3H-labelled synthetic antifibrinolytics].
Klöcking, HP; Markwardt, F; Richter, M, 1982
)
0.26
" However, pharmacokinetic studies in murine models (CD-1 mice) revealed that both SH-4-054 and SH-5-007 are susceptible to glutathione conjugation at the para position of the pentafluorophenyl group via nucleophilic aromatic substitution (SN Ar)."( Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities.
Ali, AM; Ball, DP; de Araujo, ED; Deininger, MW; Eiring, AM; Gómez-Biagi, RF; Gunning, PT; Heaton, WL; Lai, PS; O'Hare, T; Park, JS; Patel, AB; Rosa, DA; Shouksmith, AE; Vellore, NA, 2016
)
0.43
"The PreciseInhale platform used in the present study enables well-controlled powder aerosol exposures with only small amounts of micronized neat material, providing data on inhalation pharmacokinetic (PK) of NCEs at a very early stage."( Investigation of Lung Pharmacokinetic of the Novel PDE4 Inhibitor CHF6001 in Preclinical Models: Evaluation of the PreciseInhale Technology.
Acevedo, F; Brogin, G; Cenacchi, V; Fioni, A; Gerde, P; Puccini, P; Selg, E, 2018
)
0.48
"A total of 69 patients who have both idasanutlin pharmacokinetic data and UGT genotyping data were analyzed for association."( Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients.
Ou Yang, TH; So, WV; Yang, X; Zhi, J, 2019
)
0.51
" Physiologically-based pharmacokinetic models of idasanutlin and M4 have been established to simulate perpetrator and victim DDI scenarios and to evaluate whether further DDI studies in oncology patients are necessary."( Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug Interactions.
Cleary, Y; Fowler, S; Parrott, N; Tuerck, D; Umehara, K, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
"We explored the antibacterial activity of phosphanilic acid (P), an analog of sulfanilic acid, alone and in combination with trimethoprim (T; TP, 1:5) with sulfamethoxazole (S) and co-trimoxazole, the combination of this sulfonamide with trimethoprim (TS, 1:5) as the reference."( Antibacterial activity of phosphanilic acid, alone and in combination with trimethoprim.
Buck, RE; Chisholm, DR; Leitner, F; Misiek, M; Price, KE; Pursiano, TA; Tsai, YH, 1985
)
0.27
" Oral administration of K-247, 600 to 900 mg/day, was carried out in combination with antitumor treatments using MMC, FT-207, 5-FU, PSK or irradiation."( [Clinical evaluation of anticancer therapy combined with p-aminobenzoic acid-N-xyloside].
Fujimoto, S; Ishigami, H; Okui, K, 1982
)
0.26
"This work proposes a new strategy for the electrochemical detection of hepatitis C virus (HCV) RNA level and identification of HCV-1b genotype based on the site-specific cleavage of BamHI endonuclease combined with gold nanoparticles (AuNPs) signal amplification."( Ultrasensitive and selective electrochemical identification of hepatitis C virus genotype 1b based on specific endonuclease combined with gold nanoparticles signal amplification.
Cai, C; Li, W; Liu, S; Wu, P; Zhang, H, 2011
)
0.37
" Oral administration of K-247, 600 to 900 mg/day, was carried out in combination with antitumor treatments using MMC, FT-207, 5-FU, PSK or irradiation."( [Clinical evaluation of anticancer therapy combined with p-aminobenzoic acid-N-xyloside].
Fujimoto, S; Ishigami, H; Okui, K, 1982
)
0.26
" This study assessed the efficacy of RG7388 as a single-agent and in combination with chemotherapies currently used to treat neuroblastoma in a panel of neuroblastoma cell lines."( Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
Chen, L; Lunec, J; Middleton, SA; Newell, DR; Nichols, GL; Rousseau, RF; Tweddle, DA, 2015
)
0.42
"To investigate whether the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) combined with the selective MDM2 antagonist idasanutlin (RG7388) offers superior efficacy to monotherapy in treating B-lymphoid malignancies in preclinical models."( Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Bacac, M; Dangl, M; Friess, T; Herter, S; Herting, F; Klein, C; Muth, G; Sulcova, J; Umana, P, 2016
)
0.43
" This is the first study to evaluate the in vivo efficacy of the intravenous idasanutlin prodrug, RO6839921 (RG7775), both alone and in combination with temozolomide in TP53 wt orthotopic neuroblastoma models."( Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.
Berry, P; Bonner, J; Chen, L; Daga, A; Kirk, C; Lunec, J; Newell, DR; Pastorino, F; Ponzoni, M; Thomas, HD; Tweddle, DA; Veal, GJ; Wood, KM; Zhao, Y, 2019
)
0.51
" For safety reasons, it cannot be given in healthy volunteers for drug-drug interaction (DDI) explorations."( Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug Interactions.
Cleary, Y; Fowler, S; Parrott, N; Tuerck, D; Umehara, K, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" A chymotrypsin-labile peptide (N-benzoyl-L-tyrosyl-p-aminobenzoate), given at the same time, was poorly absorbed from the stomach, as shown by the low plasma p-aminobenzoic acid levels (14 +/- 2 mumol/L vs."( Gastric absorption of D-xylose in the rat: its influence on the D-xylose absorption test.
Farmer-Bailey, P; Pasquini, N; Rogers, W; Sherding, R; Stradley, R, 1986
)
0.27
" P was well absorbed parenterally but not orally in mice."( Antibacterial activity of phosphanilic acid, alone and in combination with trimethoprim.
Buck, RE; Chisholm, DR; Leitner, F; Misiek, M; Price, KE; Pursiano, TA; Tsai, YH, 1985
)
0.27
"PABA is well absorbed by the gastrointestinal tract and acetylated and conjugated in the liver to glycine before being excreted."( Preliminary assessment of glycine conjugation of para-aminobenzoic acid as a quantitative test of liver function.
Barr, SB; Duffy, LF; Kerzner, B; Seeff, L; Soldin, SJ, 1995
)
0.29
" This could guarantee a faster absorption and a better bioavailability of the active principle."( Mechanochemical synthesis of bumetanide-4-aminobenzoic acid molecular cocrystals: a facile and green approach to drug optimization.
Berbenni, V; Bruni, G; Ferrara, C; Freccero, M; Girella, A; Grande, V; Maggi, L; Maietta, M; Marini, A; Milanese, C; Mustarelli, P, 2014
)
0.67
" Thus, in this study, we aimed to develop an oral formulation for skin tissue targeting with a high bioavailability using liquid crystal (LC) dispersions comprising cubosomes of a mal-absorptive model compound, p-amino benzoic acid (PABA), which is an active element in cosmeceuticals, dietary supplements and skin disorder medicines."( Usefulness of liquid-crystal oral formulations to enhance the bioavailability and skin tissue targeting of p-amino benzoic acid as a model compound.
Ichiro, H; Kadhum, WR; Oshizaka, T; Sugibayashi, K; Todo, H, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" dose ratio was approximately one, suggesting that LY353433 was well absorbed with excellent pharmacodynamics in the rat."( LY353433, a potent, orally effective, long-acting 5-HT(4) receptor antagonist: comparison to cisapride and RS23597-190.
Bloomquist, W; Calligaro, DA; Cohen, I; Cohen, ML; Schaus, JM; Susemichel, AD; Thompson, DC, 1996
)
0.29
"Dual-label stable isotope dilution assays for the simultaneous quantification of isotopologic folates in clinical samples offer the perspective for differentiating between unlabeled folates from endogenous body pools and administered [13C5]-labeled folates from a test dose when performing bioavailability trials."( Quantification of isotope-labeled and unlabeled folates and folate catabolites in urine samples by stable isotope dilution assay.
Büttner, BE; Köhler, P; Ohrvik, VE; Rychlik, M; Witthöft, CM, 2013
)
0.39
" Here we tested two orally bioavailable small molecule inhibitors of PAI-1 (TM5275 and TM5441) for their efficacy in pre-clinical models of cancer."( Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity.
DeClerck, YA; Ichimura, A; Miyata, T; Placencio, VR, 2015
)
0.42
"We evaluated the effect of whey protein hydrolysates (WPH) on the water absorption rate in the small intestine using a rat small intestine perfusion model."( Whey protein hydrolysates enhance water absorption in the perfused small intestine of anesthetized rats.
Ito, K; Itoh, H; Noma, T; Oda, M; Yamaguchi, M; Yamaji, T, 2016
)
0.43
" The bioconcentration of OD-PABA in the fish tissues was significantly decreased with the presence of DOM indicating a reduction of OD-PABA bioavailability caused by DOM."( The effects of dissolved organic matter and feeding on bioconcentration and oxidative stress of ethylhexyl dimethyl p-aminobenzoate (OD-PABA) to crucian carp (Carassius auratus).
Liu, J; Lu, G; Ma, B; Nkoom, M; Yan, Z; Yang, H, 2018
)
0.48
"This was an open-label, single-dose, crossover clinical pharmacology study investigating the effects of strong CYP3A4 inhibition with posaconazole (Part 1), two new oral formulations (Part 2), as well as high-energy/high-fat and low-energy/low-fat meals (Part 3) on the relative bioavailability of idasanutlin."( Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Blotner, S; Chen, LC; Ejadi, S; Miller, W; Nemunaitis, J; Nichols, G; Razak, A; Vazvaei, F; Young, A; Zhi, J, 2018
)
0.48
" Bioavailability waŝ30% higher with MDDPI than SDDPI."( Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers.
Govoni, M; Lucci, G; Mariotti, F; Nandeuil, MA; Santoro, D,
)
0.13
" There was a clear dose proportionality for systemic exposure, with higher bioavailability via MDDPI, suggesting that the MDDPI provides better pulmonary drug deposition."( Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers.
Govoni, M; Lucci, G; Mariotti, F; Nandeuil, MA; Santoro, D,
)
0.13
"An orally bioavailable small molecule inhibitor of plasminogen activator inhibitor‑1 (PAI‑1) is currently being clinically assessed as a novel antithrombotic agent."( Novel oral plasminogen activator inhibitor‑1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats.
Aihara, Y; Asada, K; Douhara, A; Kaji, K; Kawaratani, H; Kitade, M; Miyata, T; Moriya, K; Namisaki, T; Nishimura, N; Noguchi, R; Takaya, H; Yoshiji, H, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
"In a previous study, we developed a multiple-unit type of oral floating dosage system, which is a new type of floating pill composed of both an effervescent layer and a swellable membrane layer coated on sustained-release pills."( A new multiple-unit oral floating dosage system. II: In vivo evaluation of floating and sustained-release characteristics with p-aminobenzoic acid and isosorbide dinitrate as model drugs.
Ichikawa, M; Kato, T; Kawahara, M; Kayano, M; Watanabe, S, 1991
)
0.28
"A simple and rapid spectrophotometric procedure has been developed for the determination of four local anaesthetics containing a free primary amine moiety and of procainamide hydrochloride as the drug substances and in dosage forms."( Use of 7,7,8,8-tetracyanoquinodimethane for spectrophotometric determination of certain local anaesthetics and procainamide hydrochloride.
Hassan, HY; Hussein, SA; Mohamed, AM; Mohamed, HA, 1991
)
0.28
" Amounts of PABA excreted in urine during 6 h after dosing were 21."( Basic studies on ursodeoxycholyl-para-aminobenzoic acid for evaluation of intestinal microflora.
Akazawa, F; Maeda, Y; Masaoka, Y; Matsugu, Y; Okajima, M; Takahashi, M; Tashiro, H; Toyota, K; Yoshioka, S, 1991
)
0.28
"There are presently no standards for in vitro research dealing with the release and delivery of drugs from semisolid dosage forms, largely because of inherent experimental difficulties."( Drug transport from thin applications of topical dosage forms: development of methodology.
Addicks, WJ; Chiang, CM; Flynn, GL; Weiner, N, 1988
)
0.27
" Urine samples were obtained from healthy Chinese volunteers after oral dosing of 200 mg PABA which was used as a model substance for metabolic investigation of N-acetylation and other conjugation reactions."( High performance liquid chromatographic characterisation and quantitation of p-aminobenzoic acid N-acetylation in Chinese subjects.
Chan, K,
)
0.13
" A similar gene dose-response relationship was exhibited by the polymorphic N-acetyltransferase enzyme toward isoniazid and procainamide."( Biochemical investigation of the basis for the genetic N-acetylation polymorphism in the inbred hamster.
Ferguson, RJ; Hein, DW; Kirlin, WG; Weber, WW, 1985
)
0.27
" This metabolite accounted for 50% of the administered dose in orally dosed animals and 31% in iv dosed animals."( Inosiplex: metabolism and excretion of the dimethylaminoisopropanol and p-acetamidobenzoic acid components in rhesus monkeys.
Pfadenhauer, EH; Streeter, DG,
)
0.13
"Two different diets for the host and three drug dosage regimens were used to select lines resistant to sulfadoxine and pyrimethamine from the parent strain of the rodent malaria parasite Plasmodium berghei [the N (K173) strain]."( Plasmodium berghei: diet and drug dosage regimens influencing selection of drug-resistant parasites in mice.
Merkli, B; Richle, R, 1983
)
0.27
" 2 Reduction of 4-nitrobenzoic acid was significantly decreased by antibiotic pretreatment; the mean decrease in reduction was 81% for animals doses orally and 73% for intraperitoneally dosed marmosets."( Influence of the gut microflora on the metabolism of 4-nitrobenzoic acid in the marmoset.
James, SP; Kuzniar, EJ, 1981
)
0.26
" Plasma p-aminobenzoic acid (PABA) and xylose concentrations were determined before, and at 30, 60, 90, 120, 150, and 180 minutes after, a solution of bentiromide (1 g/100 ml) and D-xylose (10 g/100 ml) was given orally at a dosage of 5 ml/kg of body weight."( Bentiromide:xylose test in healthy cats.
Johnson, SE; Rogers, WA; Sherding, RG; Stradley, RP, 1982
)
0.26
" Including one patient receiving a high dosage (over 200 g totally) of K-247, in all cases, no appreciable side effect causing suspension of the administration was recognized."( [Clinical trial of K-247].
Kakuta, H; Kanamaru, R; Kanbe, M; Mitachi, Y; Sato, T; Takahashi, K; Wakui, A, 1982
)
0.26
" The data obtained in the dose-response study of cetaben revealed a significant rise in the activities of peroxisomal enzymes in both the liver and kidney at doses of 50-100 mg/kg body wt administered over 10 days, but the maximal effect was observed at 250 mg/kg."( Cetaben and fibrates both influence the activities of peroxisomal enzymes in different ways.
Chandoga, J; Hampl, L; Hocman, G; Rojeková, I, 1994
)
0.29
" In a mouse model of influenza, 5 did not protect the mice from weight loss due to the influenza virus when dosed intranasally."( Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
Babu, YS; Bantia, S; Chand, P; Chu, N; Cole, LB; Kotian, PL; Laver, WG; Montgomery, JA; Pathak, VP; Petty, SL; Shrout, DP; Walsh, DA; Walsh, GM, 1997
)
0.3
"Elimination of drug molecules via tubular secretion is an important pharmacokinetic parameter especially for oral dosage forms where an extremely short half-life would prevent their application."( Inhibition of the conjugation of PABA with glycine in vitro by sulfamoyl benzoic acids, sulfonamides, and penicillins and its relation to tubular secretion.
Ehlert, C; Seydel, JK; Strunz, H; Visser, K; Wiese, M, 1998
)
0.3
" The skin surface was not protected during the absorption dosing period."( Percutaneous absorption of salicylic acid, theophylline, 2, 4-dimethylamine, diethyl hexyl phthalic acid, and p-aminobenzoic acid in the isolated perfused porcine skin flap compared to man in vivo.
Maibach, H; Melendres, J; Riviere, JE; Sedik, L; Wester, RC, 1998
)
0.3
" Reversed sucrose ester vesicles offer new perspectives regarding the development of novel pharmaceutical dosage forms."( Stable reversed vesicles in oil: characterization studies and encapsulation of model compounds.
de Vrind, J; De Vringer, T; Mollee, H, 2000
)
0.31
" Protocol 2 examined, if the last dosage of p-aminobenzoic acid (PABA) could be advanced in the old to allow for a delayed age-dependent urinary excretion of PABA."( Para-aminobenzoic acid used as a marker for completeness of 24 hour urine: assessment of control limits for a specific HPLC method.
Fagt, S; Jakobsen, J; Ovesen, L; Pedersen, AN, 1997
)
0.3
" Protocol 2: compared urinary PABA excretion in two groups of 80 y old subjects who had their last PABA dosage administered at 15."( Para-aminobenzoic acid used as a marker for completeness of 24 hour urine: assessment of control limits for a specific HPLC method.
Fagt, S; Jakobsen, J; Ovesen, L; Pedersen, AN, 1997
)
0.3
"An advanced dosage schedule for PABA in the aged is recommended."( Para-aminobenzoic acid used as a marker for completeness of 24 hour urine: assessment of control limits for a specific HPLC method.
Fagt, S; Jakobsen, J; Ovesen, L; Pedersen, AN, 1997
)
0.3
"Acetyl acetone is introduced as a new coupling agent for the spectrophotometric determination of some chemotherapeutic agents, such as metoclopramide, dapsone, p-aminobenzoic acid, and cisapride in both pure and dosage forms."( Spectrophotometric determination of some chemotherapeutic agents using acetyl acetone.
Manju, B; Revanasiddappa, HD, 2002
)
0.31
"There is a gradual decline of PABA recovery with age that cannot be overcome by advancing the dosage schedule."( Para-aminobenzoic acid (PABA) used as a marker for completeness of 24 hour urine: effects of age and dosage scheduling.
Jakobsen, J; Ovesen, L; Pedersen, AN, 2003
)
0.32
" Recovery of both the drugs in tablet dosage form and spiked drugs in plasma were > or =99."( Simultaneous determination of HIV-protease inhibitors lamivudine and zidovudine in pharmaceutical formulations by micellar electrokinetic chromatography.
Azhaguvel, S; Sekar, R, 2005
)
0.33
" Then the different dosage BCG with or without antifibrinolytic agents was regular instilled into bladders (once a week, then once a month after 6 times)."( [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Chen, J; Ding, GQ; Jin, XD; Lu, J; Shen, ZJ; Shi, SF, 2005
)
0.33
" Even if the dosage of BCG was reduced by half, the efficacy didn't changed."( [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Chen, J; Ding, GQ; Jin, XD; Lu, J; Shen, ZJ; Shi, SF, 2005
)
0.33
" Permeation issues for topical delivery systems of such effects are occasionally problematic, and in view of the fact that microemulsions are potential carriers for transdermal delivery system, the objective of this study was to design an optimal microemulsion formulation by in vitro permeation study for hesperetin topical dosage form and determine its topical photoprotective effect and skin irritation by in vivo study."( In vitro permeation and in vivo whitening effect of topical hesperetin microemulsion delivery system.
Huang, CT; Huang, YB; Lee, KF; Tsai, YH; Wu, PC, 2010
)
0.36
" This melt granulation was followed with direct compression to generate oral solid dosage forms."( Continuous, simultaneous cocrystallization and formulation of Theophylline and 4-Aminobenzoic acid pharmaceutical cocrystals using twin screw melt granulation.
Croker, DM; Shaikh, R; Walker, GM, 2019
)
0.74
" Amounts of PABA excreted in urine during 6 h after dosing were 21."( Basic studies on ursodeoxycholyl-para-aminobenzoic acid for evaluation of intestinal microflora.
Akazawa, F; Maeda, Y; Masaoka, Y; Matsugu, Y; Okajima, M; Takahashi, M; Tashiro, H; Toyota, K; Yoshioka, S, 1991
)
0.28
" Urine samples were obtained from healthy Chinese volunteers after oral dosing of 200 mg PABA which was used as a model substance for metabolic investigation of N-acetylation and other conjugation reactions."( High performance liquid chromatographic characterisation and quantitation of p-aminobenzoic acid N-acetylation in Chinese subjects.
Chan, K,
)
0.13
" This metabolite accounted for 50% of the administered dose in orally dosed animals and 31% in iv dosed animals."( Inosiplex: metabolism and excretion of the dimethylaminoisopropanol and p-acetamidobenzoic acid components in rhesus monkeys.
Pfadenhauer, EH; Streeter, DG,
)
0.13
" 2 Reduction of 4-nitrobenzoic acid was significantly decreased by antibiotic pretreatment; the mean decrease in reduction was 81% for animals doses orally and 73% for intraperitoneally dosed marmosets."( Influence of the gut microflora on the metabolism of 4-nitrobenzoic acid in the marmoset.
James, SP; Kuzniar, EJ, 1981
)
0.26
" Plasma p-aminobenzoic acid (PABA) and xylose concentrations were determined before, and at 30, 60, 90, 120, 150, and 180 minutes after, a solution of bentiromide (1 g/100 ml) and D-xylose (10 g/100 ml) was given orally at a dosage of 5 ml/kg of body weight."( Bentiromide:xylose test in healthy cats.
Johnson, SE; Rogers, WA; Sherding, RG; Stradley, RP, 1982
)
0.26
" Including one patient receiving a high dosage (over 200 g totally) of K-247, in all cases, no appreciable side effect causing suspension of the administration was recognized."( [Clinical trial of K-247].
Kakuta, H; Kanamaru, R; Kanbe, M; Mitachi, Y; Sato, T; Takahashi, K; Wakui, A, 1982
)
0.26
" The data obtained in the dose-response study of cetaben revealed a significant rise in the activities of peroxisomal enzymes in both the liver and kidney at doses of 50-100 mg/kg body wt administered over 10 days, but the maximal effect was observed at 250 mg/kg."( Cetaben and fibrates both influence the activities of peroxisomal enzymes in different ways.
Chandoga, J; Hampl, L; Hocman, G; Rojeková, I, 1994
)
0.29
" dosing with responses returning to control by 16 hr, indicative of long duration receptor blockade."( LY353433, a potent, orally effective, long-acting 5-HT(4) receptor antagonist: comparison to cisapride and RS23597-190.
Bloomquist, W; Calligaro, DA; Cohen, I; Cohen, ML; Schaus, JM; Susemichel, AD; Thompson, DC, 1996
)
0.29
" After daily topical dosing of Tes for 6 days, the plasma Tes levels were determined and the transdermal flux was calculated by correcting the pseudo steady-state plasma concentration versus time profile with the clearance of an iv dose within the same swine."( Enhanced transdermal delivery of sex hormones in swine with a novel topical aerosol.
Finnin, BC; Morgan, TM; Parr, RA; Reed, BL, 1998
)
0.3
" There were no significant differences between the two groups with respect to ease of intubation, procedure performance, procedure duration, and dosing of midazolam or meperidine."( Topical pharyngeal anesthesia does not improve upper gastrointestinal endoscopy in conscious sedated patients.
Davis, DE; Jones, MP; Kubik, CM, 1999
)
0.3
" Then the different dosage BCG with or without antifibrinolytic agents was regular instilled into bladders (once a week, then once a month after 6 times)."( [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Chen, J; Ding, GQ; Jin, XD; Lu, J; Shen, ZJ; Shi, SF, 2005
)
0.33
" Even if the dosage of BCG was reduced by half, the efficacy didn't changed."( [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Chen, J; Ding, GQ; Jin, XD; Lu, J; Shen, ZJ; Shi, SF, 2005
)
0.33
" Permeation issues for topical delivery systems of such effects are occasionally problematic, and in view of the fact that microemulsions are potential carriers for transdermal delivery system, the objective of this study was to design an optimal microemulsion formulation by in vitro permeation study for hesperetin topical dosage form and determine its topical photoprotective effect and skin irritation by in vivo study."( In vitro permeation and in vivo whitening effect of topical hesperetin microemulsion delivery system.
Huang, CT; Huang, YB; Lee, KF; Tsai, YH; Wu, PC, 2010
)
0.36
" We detected six of the in vitro products and their respective glucuronides in murine plasma after dosing BEN."( Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines.
Anyang, BN; Beumer, JH; Covey, JM; Egorin, MJ; Eiseman, JL; Parise, RA, 2013
)
0.39
" There was no acute toxicity even at the highest dosage (1000 mg/kg)."( Gastroprotective activity of ethyl-4-[(3,5-di-tert-butyl-2-hydroxybenzylidene) amino]benzoate against ethanol-induced gastric mucosal ulcer in rats.
Abdulla, MA; Ablat, A; Al-Wajeeh, NS; Bardi, DA; Hajrezaie, M; Halabi, MF; Hassandarvish, P; Norazit, A; Shakir, RM, 2014
)
0.4
"Antitumor clinical activity has been demonstrated for the MDM2 antagonist RG7112, but patient tolerability for the necessary daily dosing was poor."( Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach.
Adames, V; Filipovic, Z; Garrido, R; Glenn, K; Heimbrook, D; Higgins, B; Hussain, S; Kolinsky, K; Lee, E; Linn, M; Meille, C; Packman, K; Tannu, S; Tovar, C; Vassilev, L; Walz, A, 2014
)
0.4
"A pharmacokinetic-pharmacodynamic (PKPD) model was developed on the basis of preclinical data to determine alternative dosing schedule requirements for optimal RG7388-induced antitumor activity."( Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach.
Adames, V; Filipovic, Z; Garrido, R; Glenn, K; Heimbrook, D; Higgins, B; Hussain, S; Kolinsky, K; Lee, E; Linn, M; Meille, C; Packman, K; Tannu, S; Tovar, C; Vassilev, L; Walz, A, 2014
)
0.4
" In initial efficacy testing, daily dosing at 30 mg/kg and twice a week dosing at 50 mg/kg of RG7388 were statistically equivalent in our tumor model."( Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach.
Adames, V; Filipovic, Z; Garrido, R; Glenn, K; Heimbrook, D; Higgins, B; Hussain, S; Kolinsky, K; Lee, E; Linn, M; Meille, C; Packman, K; Tannu, S; Tovar, C; Vassilev, L; Walz, A, 2014
)
0.4
" Alternative dosing regimens and combination with other targeted agents are needed to achieve successful development of nutlin in the clinical setting."( Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin.
Chaire, V; Chibon, F; Coindre, JM; Hostein, I; Italiano, A; Lagarde, P; Laroche, A; Lesluyes, T; Lucchesi, C; Neuville, A; Tran-Cong, K, 2015
)
0.42
" To optimize its dosing conditions, a number of clinical pharmacology characteristics were examined in this multi-center trial in patients with advanced solid tumors."( Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Blotner, S; Chen, LC; Ejadi, S; Miller, W; Nemunaitis, J; Nichols, G; Razak, A; Vazvaei, F; Young, A; Zhi, J, 2018
)
0.48
" Modeling and simulation then compared OD and BID dosing via MDDPI."( Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers.
Govoni, M; Lucci, G; Mariotti, F; Nandeuil, MA; Santoro, D,
)
0.13
" The PK simulation confirmed dose proportionality; the same total daily dose OD or BID via MDDPI resulted in similar 24 hours exposure, with BID dosing providing smaller fluctuation and lower maximum concentration."( Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers.
Govoni, M; Lucci, G; Mariotti, F; Nandeuil, MA; Santoro, D,
)
0.13
" BID dosing was associated with a better exposure profile."( Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers.
Govoni, M; Lucci, G; Mariotti, F; Nandeuil, MA; Santoro, D,
)
0.13
" Overall, RO6839921 had a favourable pharmacokinetic profile consistent with intermittent dosing and was well tolerated alone and in combination."( Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.
Berry, P; Bonner, J; Chen, L; Daga, A; Kirk, C; Lunec, J; Newell, DR; Pastorino, F; Ponzoni, M; Thomas, HD; Tweddle, DA; Veal, GJ; Wood, KM; Zhao, Y, 2019
)
0.51
" Methods Patients were evaluated on a 5-day dosing schedule every 28 days."( A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
Abdul Razak, AR; Blotner, S; Chen, LC; Gore, L; Higgins, B; Miller, WH; Uy, GL; Young, AM, 2020
)
0.56
" Dose-limiting toxicities were nausea/vomiting and myelosuppression; myelosuppression was more frequent with QD dosing and associated with pharmacokinetic exposure."( Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Bang, YJ; Blay, JY; Blotner, S; Chen, LC; Gietema, JA; Higgins, B; Hirte, HW; Italiano, A; Jamois, C; Mileshkin, LR; Miller, WH; Nichols, GL; Petry, C; Schmitt, C; Siu, LL; Yang, QJ, 2021
)
0.62
" Overall, the idasanutlin dosing regimen showed clinical activity and rapidly reduced JAK2 allele burden in patients with HU-resistant/- intolerant PV but was associated with low-grade gastrointestinal toxicity, leading to poor long-term tolerability."( The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.
Bellini, M; Burbury, K; El-Galaly, TC; Gerds, A; Gupta, V; Higgins, B; Huw, LY; Jamois, C; Katakam, S; Kovic, B; Maffioli, M; Mascarenhas, J; Mesa, R; Palmer, J; Passamonti, F; Ross, DM; Vannucchi, AM; Wonde, K; Yacoub, A, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (55 Product(s))

Product Categories

Product CategoryProducts
Professional Supplements10
Vitamins & Supplements39
Active Lifestyle & Fitness6

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Allergy Research Group Multi-Vi-Min without Copper & Iron -- 150 Vegetarian CapsulesAllergy Research GroupProfessional SupplementsPABA, Vitamin C, Biotin, Boron, Vitamin D3, Chromium, Vitamin E, Folic Acid, Vitamin E, Glutamic Acid, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Allergy Research Group Super Vitamin B Complex -- 120 Vegetarian CapsulesAllergy Research GroupProfessional SupplementsPABA, Biotin, Folic Acid, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Best Naturals B-100 Complex -- 120 TabletsBest NaturalsVitamins & SupplementsPABA, Biotin, Choline, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin B2, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
Beverly International Super Pak -- 30 PacketsBeverly InternationalActive Lifestyle & FitnessPara-Aminobenzoic Acid, Vitamin C, Betaine HCl, Biotin, Chloride, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, L-Glutamic Acid, Pepsin, Inositol, Iodine, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Bluebonnet Nutrition B-Complex 100 -- 100 Vegetable CapsulesBluebonnet NutritionVitamins & SupplementsPABA, Biotin, Choline, Folate, Inositol, Vitamin B3, PABA, Pantothenic Acid, Vitamin B6, Vitamin B2, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
Bluebonnet Nutrition B-Complex 50 -- 100 Vegetable CapsulesBluebonnet NutritionVitamins & SupplementsPABA, Biotin, Choline, Folate, Inositol, Vitamin B3, PABA, Pantothenic Acid, Vitamin B6, Vitamin B2, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
Bluebonnet Nutrition CellularActive® Coenzyme B-Complex -- 100 Vcaps®Bluebonnet NutritionVitamins & SupplementsPABA, Biotin, Choline, riboflavin 5' phosphate, inositol hexanicotinate, Inositol, Vitamin B3, niacinamide, PABA, Pantothenic Acid, pyridoxal 5' phosphate, pyridoxine HCl, Vitamin B6, Vitamin B2, cocarboxylase, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
Bluebonnet Nutrition Multi One Single Daily Multiple -- 120 Vegetable CapsulesBluebonnet NutritionVitamins & SupplementsPABA, Vitamin C, Biotin, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Manganese, Molybdenum, Vitamin B3, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
CeliAct Optimizing Nutrition for People with Celiac Disease -- 180 TabletsCeliActVitamins & Supplements Lipase, Para Aminobenzoic Acid, Vitamin C, Biotin, Boron, Chromium, Vitamin E, Folic Acid, Vitamin E, L-Glutamic Acid, Inositol, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Country Life Chewable Adult Multi -- 60 WafersCountry LifeVitamins & SupplementsPABA, Vitamin C, Biotin, calcium ascorbate, calcium citrate, Choline, Chromium, Vitamin E, riboflavin 5' phosphate, Folic Acid, Vitamin E, Inositol, Manganese, Niacin, niacinamide, PABA, Pantothenic Acid, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Country Life Coenzyme B-Complex -- 120 Vegan CapsulesCountry LifeVitamins & SupplementsPABA, Biotin, d-calcium pantothenate, Choline, dibencozide, riboflavin 5' phosphate, Folate, Inositol, Niacin, PABA, pantethine, Pantothenic Acid, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, Riboflavin, thiamine hydrochloride, Thiamin, alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Country Life Coenzyme B-Complex -- 60 Vegan CapsulesCountry LifeVitamins & SupplementsPABA, Biotin, Choline, dibencozide, riboflavin 5' phosphate, Folate, Inositol, Niacin, PABA, pantethine, Pantothenic Acid, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, Riboflavin, thiamine hydrochloride, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
DaVinci Laboratories B Complex-75 -- 60 CapsulesDaVinci LaboratoriesProfessional SupplementsPABA, Biotin, Choline, Folic Acid, Inositol, Niacinamide, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
DaVinci Laboratories Spectra Man Multi -- 120 TabletsDaVinci LaboratoriesProfessional Supplements Lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, L-Cysteine, Vitamin E, Folic Acid, Gamma Linolenic Acid, Vitamin E, L-Glutamine, Hesperidin, Inositol, Iodine, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
DaVinci Laboratories Spectra™ Multivitamins for Adults -- 240 TabletsDaVinci LaboratoriesProfessional Supplements Lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, L-Cysteine, Vitamin E, Folic Acid, Vitamin E, L-Glutamine, Hesperidin, Inositol, Iodine, Linoleic Acid, Manganese, Molybdenum, Niacin, Nickel, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
DaVinci Laboratories Spectra™ Senior Multi -- 180 TabletsDaVinci LaboratoriesProfessional Supplements lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, Coenzyme Q10, L-Cysteine, Vitamin E, Folic Acid, Gamma Linolenic Acid, Vitamin E, Glutamic Acid, Hesperidin, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
DaVinci Laboratories Spectra™ Woman -- 120 TabletsDaVinci LaboratoriesProfessional Supplements lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Biotin, Boron, Vitamin D3, Choline, Chromium, L-Cysteine, Vitamin E, Folic Acid, Gamma Linolenic Acid, Vitamin E, L-Glutamine, Hesperidin, Inositol, Iodine, Manganese, Molybdenum, Niacin, Nickel, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
DaVinci Laboratories Ultimate Prenatal Multi -- 150 TabletsDaVinci LaboratoriesProfessional Supplements lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, L-Cysteine, Vitamin E, Folic Acid, Vitamin E, L-Glutamine, Hesperidin, Inositol, Iodine, Linoleic Acid, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Deva Vegan Hair Nails and Skin -- 90 TabletsDevaVitamins & SupplementsPABA, Vitamin C, Biotin, Choline, L-cysteine, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Vitamin B3, PABA, Vitamin B5, Vitamin B6, Vitamin B2, Beta Sitosterol, Vitamin B1, Alpha Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Dr. Mercola Whole Food Multivitamin Plus -- 240 TabletsDr. MercolaProfessional SupplementsPABA, Ascorbyl Palmitate, Vitamin C, Betaine, Biotin, Boron, Vitamin D3, Choline, Chromium, Folate, Glutamic Acid, Hesperidin, Inositol, Iodine, Manganese, Molybdenum, Niacin, Niacinamide, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Strontium, Thiamin, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Dr. Mercola Whole-Food Multivitamin for Women -- 240 TabletsDr. MercolaProfessional SupplementsPABA, Ascorbyl Palmitate, Vitamin C, Betaine, Biotin, Boron, Vitamin D3, Choline, Chromium, Folate, Glutamic Acid, Hesperidin, Inositol, Iodine, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Strontium, Thiamin, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Evlution Nutrition VitaMode -- 120 TabletsEvlution NutritionActive Lifestyle & Fitness Lipase, PABA, Vitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Futurebiotics Hair Skin & Nails® for Men -- 135 TabletsFuturebioticsVitamins & Supplementspara-Aminobenzoic Acid, Vitamin C, Biotin, Vitamin D3, Choline, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Futurebiotics Hair, Skin and Nails® -- 75 TabletsFuturebioticsVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Betaine, Biotin, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Manganese, Methionine, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Futurebiotics Hi-Energy Multi For Men™ -- 120 TabletsFuturebioticsVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Biotin, Chloride, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Futurebiotics Multi Vitamin Energy Plus® For Women -- 60 TabletsFuturebioticsVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Biotin, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Jigsaw Health Activated B with SRT® -- 120 TabletsJigsaw HealthVitamins & SupplementsPABA, Biotin, Choline, Folate, Microcrystalline cellulose, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
KAL Stress B-Complex -- 100 TabletsKALVitamins & SupplementsPABA, Vitamin C, Biotin, Cellulose, Choline, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, stearic acid, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Life Extension BioActive Complete B-Complex -- 60 Vegetarian CapsulesLife ExtensionVitamins & SupplementsPABA, Biotin, D-calcium pantothenate, dicalcium phosphate, calcium sulfate, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, stearic acid, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Lifetime All One Rice Base Multiple Vitamin & Mineral Powder Unflavored -- 2.2 lbsLifetimeVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Kelp, Beta Carotene, Betaine HCl, Biotin, Calcium Pantothenate, Dicalcium Phosphate, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Calcium Carbonate, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Potassium Iodide, Vitamin B6, Retinol Acetate, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
Lifetime Multiple Vitamin & Mineral Powder Unflavored -- 2.2 lbsLifetimeVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Kelp, Biotin, Calcium Pantothenate, Dicalcium Phosphate, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Calcium Carbonate, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
Mason Natural Daily Multiple Vitamins With Iron -- 365 TabletsMason NaturalVitamins & SupplementsPABA, Vitamin C, Vitamin E, Folate, Vitamin E, Microcrystalline cellulose, Vitamin B3, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B2, stearic acid, Vitamin B1, titanium dioxide, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
NutriBiotic Broken Cell Wall Chlorella Microalgae -- 500 mg - 300 Vegan TabletsNutriBioticVitamins & SupplementsPABA, Biotin, Chlorophyll, Inositol, Iodine, Niacin, PABA, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, stearic acid, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
NutriBiotic Multi Vitamins & Minerals -- 180 CapsulesNutriBioticVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Glucono delta lactone, Biotin, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, calcium carbonate, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B2, Selenium, montmorillonite, Thiamin, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
NutriCology Super B Vitamins Non Yeast or Corn Derived -- 120 Vegetarian CapsulesNutriCologyVitamins & SupplementsPABA, Biotin, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Optimum Nutrition Opti-Men Multivitamin for Men -- 150 TabletsOptimum NutritionActive Lifestyle & Fitness Lipase, PABA, Alpha-Carotene, Vitamin C, beta carotene, Biotin, Boron, Choline, Chromium, Cryptoxanthin, L-Cystine, Vitamin E, Folic Acid, Vitamin E, L-Glutamine, Microcrystalline cellulose, Inositol, Iodine, L-Isoleucine, Lutein, Lycopene, L-Lysine, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Alpha-Lipoic Acid, L-Valine, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Optimum Nutrition Opti-Men Multivitamin for Men -- 240 TabletsOptimum NutritionActive Lifestyle & Fitness Lipase, PABA, Alpha-Carotene, Vitamin C, beta carotene, Biotin, Boron, Choline, Chromium, Cryptoxanthin, L-Cystine, Vitamin E, Folate, Vitamin E, L-Glutamine, Microcrystalline cellulose, Inositol, Iodine, L-Isoleucine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Alpha-Lipoic Acid, L-Valine, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Optimum Nutrition Opti-Men Multivitamin for Men -- 90 TabletsOptimum NutritionActive Lifestyle & FitnessPABA, Alpha-Carotene, Vitamin C, beta carotene, Biotin, Boron, Chromium, Cryptoxanthin, L-Cystine, Vitamin E, Folate, Vitamin E, L-Glutamine, glycerine, Microcrystalline cellulose, Inositol, Iodine, L-Isoleucine, Lutein, Lycopene, L-Lysine, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Alpha-Lipoic Acid, L-Valine, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Optimum Nutrition Serious Mass Protein Powder Supplement Chocolate -- 16 ServingsOptimum NutritionActive Lifestyle & FitnessPABA, acesulfame potassium, acesulfame potassium, d-alpha tocopheryl succinate, Vitamin C, beta carotene, Biotin, calcium citrate, d-calcium pantothenate, di-calcium phosphate, cholecalciferol, Choline, Chromium, copper gluconate, Vitamin E, ferrous fumarate, folic acid, Vitamin E, L-Glutamine, Inositol, Iodine, Maltodextrin, Manganese, Molybdenum, Niacin, niacinamide, PABA, Pantothenic Acid, Phosphorus, potassium iodide, pyridoxine hydrochloride, Vitamin B6, Vitamin A, Riboflavin, Selenium, selenomethionine, Thiamin, cyanocobalamin, Vitamin B62024-11-29 10:47:42
Solaray B-Complex 100 -- 100 VegCapsSolarayVitamins & SupplementsPABA, Biotin, Chlorine, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Swolverine B-Complex -- 30 TabletsSwolverineVitamins & SupplementsPara Aminobenzoic Acid, Biotin, Choline, Folate, Inositol, Calcium carbonate, Niacin, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Terry Naturally Clinical Essentials Multi-Vitamin & Minerals -- 60 TabletsTerry NaturallyVitamins & SupplementsPABA, citric acid, Vitamin C, Benfotiamine, Biotin, Boron, calcium ascorbate, calcium fructoborate, dicalcium phosphate, Vitamin D3, Choline, Chromium, citric acid, Vitamin E, Folate, Vitamin E, glycerol monostearate, glycine, Microcrystalline cellulose, Inositol, Iodine, maltodextrin, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Thompson B 100 Complex Timed-Release -- 60 TabletsThompsonVitamins & SupplementsPABA, Biotin, Cellulose, Choline, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, stearic acid, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Thompson B 50 Complex -- 60 Vegetarian CapsulesThompsonVitamins & SupplementsPABA, Biotin, Folic Acid, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Tropical Oasis Mega Premium Multi-Vitamin -- 32 fl ozTropical OasisVitamins & SupplementsPABA, Vitamin C, Biotin, Choline, CoQ10, Vitamin E, Folate, Vitamin E, Inositol, Vitamin B3, PABA, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Vitamin B2, Vitamin B1, Vitamin B12, Vitamin B6, xylitol2024-11-29 10:47:42
Twinlab Stress B-Complex Caps -- 100 CapsulesTwinlabVitamins & SupplementsPABA, Vitamin C, Biotin, Folic Acid, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin B2, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Twinlab Stress B-Complex Caps -- 250 CapsulesTwinlabVitamins & SupplementsPABA, Vitamin C, Biotin, Choline, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
VegLife Vegan B-Complex -- 100 TabletsVegLifeVitamins & SupplementsPABA, Biotin, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, stearic acid, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
VegLife Vegan One Multiple with Iron -- 60 TabletsVegLifeVitamins & SupplementsPABA, Vitamin C, Biotin, calcium citrate, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamine, calcium phosphate, Vitamin B12, Vitamin B62024-11-29 10:47:42
VegLife Vegan One™ Multiple Iron-Free -- 60 TabletsVegLifeVitamins & SupplementsPABA, Vitamin C, Biotin, calcium citrate, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, montmorillonite clay, stearic acid, Thiamine, calcium phosphate, Vitamin B12, Vitamin B62024-11-29 10:47:42
VegLife Vital Teen™ Boys Multiple -- 60 Vegan CapsulesVegLifeVitamins & SupplementsPABA, Vitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, L-carnitine, maltodextrin, Manganese, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
VegLife Vital Teen™ Girls Multiple -- 60 Vegan CapsulesVegLifeVitamins & SupplementsPABA, Vitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Iodine, maltodextrin, Manganese, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
World Organic Hair-Nu Supplement -- 120 TabletsWorld OrganicVitamins & SupplementsPABA, Vitamin C, Biotin, Di-calcium phosphate, Choline, L-Cysteine, Folate, Inositol, Iodine, PABA, Pantothenic Acid, Vitamin B6, stearic acid, Vitamin B62024-11-29 10:47:42
World Organic Ultra-B Liquid -- 16 fl ozWorld OrganicVitamins & SupplementsPABA, Biotin, Choline, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Zhou Daily Boost -- 30 Vegetarian CapsulesZhouVitamins & SupplementsPABA, Vitamin C, Biotin, cellulose, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, maltodextrin, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamine, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42

Roles (4)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
aromatic amino-acid zwitterionAn amino acid zwitterion obtained by transfer of a proton from the carboxy to the amino group of any aromatic amino-acid.
aminobenzoic acid
aminobenzoate
aromatic amino-acid anionAn aromatic amino acid whose alpha-carboxylic acid group is ionized (non-protonated).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (21)

PathwayProteinsCompounds
Acetaminophen synthesis07
Folate biosynthesis08
Tryptophan metabolism2342
Folate biosynthesis029
Tetrahydrofolate biosynthesis II128
4-aminobenzoate biosynthesis I07
4-aminobenzoate biosynthesis37
superpathway of tetrahydrofolate biosynthesis1029
tetrahydrofolate biosynthesis313
tetrahydrofolate biosynthesis II1232
tetrahydrofolate biosynthesis I013
thyroid hormone biosynthesis524
4-hydroxymandelate degradation638
superpathway of aromatic compound degradation via 2-hydroxypentadienoate5095
superpathway of aromatic compound degradation via 3-oxoadipate3681
tetrahydrofolate biosynthesis742
superpathway of tetrahydrofolate biosynthesis1965
4-aminobenzoate biosynthesis711
superpathway of tetrahydrofolate biosynthesis and salvage1370
superpathway of candicidin biosynthesis1530
candicidin biosynthesis1021
superpathway of ubiquinol-6 biosynthesis (eukaryotic)527
superpathway of chorismate metabolism56186
ubiquinol-6 biosynthesis from 4-aminobenzoate (yeast)522
p-aminobenzoate biosynthesis27
tetrahydrofolate biosynthesis II2333
tetrahydrofolate biosynthesis I028
superpathway of chorismate576

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.31620.003245.467312,589.2998AID2517
USP1 protein, partialHomo sapiens (human)Potency100.00000.031637.5844354.8130AID743255
AR proteinHomo sapiens (human)Potency36.42610.000221.22318,912.5098AID588515; AID588516
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.12590.001318.074339.8107AID926; AID938
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency8.48520.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency38.39000.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen nuclear receptor alphaHomo sapiens (human)Potency54.67220.000229.305416,493.5996AID743069
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency34.20150.001723.839378.1014AID743083
Histone H2A.xCricetulus griseus (Chinese hamster)Potency31.69370.039147.5451146.8240AID1224845
chromobox protein homolog 1Homo sapiens (human)Potency2.81840.006026.168889.1251AID540317
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency5.62340.794321.275750.1187AID624246
gemininHomo sapiens (human)Potency0.13000.004611.374133.4983AID624297
Cellular tumor antigen p53Homo sapiens (human)Potency68.24100.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)3.80000.03403.987110.0000AID1628080
Cytochrome P450 1B1Homo sapiens (human)IC50 (µMol)120.00000.00130.86969.9000AID1306443
Chain A, Toluene-4-monooxygenase system protein APseudomonas mendocinaKi5.00005.00005.00005.0000AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyprotein Kd40.00002.90002.90002.9000AID146231
Dihydropteroate synthase Bacillus anthracisKd5.62005.62005.62005.6200AID444561
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (207)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
nucleobase-containing compound metabolic processThiopurine S-methyltransferaseHomo sapiens (human)
xenobiotic metabolic processThiopurine S-methyltransferaseHomo sapiens (human)
methylationThiopurine S-methyltransferaseHomo sapiens (human)
xenobiotic catabolic processThiopurine S-methyltransferaseHomo sapiens (human)
succinate metabolic processSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
glutamate metabolic processSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
central nervous system developmentSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
gamma-aminobutyric acid catabolic processSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
post-embryonic developmentSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
synaptic transmission, GABAergicSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
response to hypoxia4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
copulation4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
locomotory behavior4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
response to xenobiotic stimulus4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
gamma-aminobutyric acid metabolic process4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
gamma-aminobutyric acid biosynthetic process4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
response to iron ion4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
negative regulation of gamma-aminobutyric acid secretion4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
cerebellum development4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
positive regulation of heat generation4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
positive regulation of insulin secretion4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
negative regulation of dopamine secretion4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
response to nicotine4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
exploration behavior4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
response to ethanol4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
negative regulation of blood pressure4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
positive regulation of dopamine metabolic process4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
behavioral response to cocaine4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
positive regulation of uterine smooth muscle contraction4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
positive regulation of inhibitory postsynaptic potential4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
positive regulation of prolactin secretion4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
positive regulation of aspartate secretion4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
gamma-aminobutyric acid catabolic process4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1B1Homo sapiens (human)
angiogenesisCytochrome P450 1B1Homo sapiens (human)
trabecular meshwork developmentCytochrome P450 1B1Homo sapiens (human)
DNA modificationCytochrome P450 1B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1B1Homo sapiens (human)
nitric oxide biosynthetic processCytochrome P450 1B1Homo sapiens (human)
cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to nutrientCytochrome P450 1B1Homo sapiens (human)
steroid metabolic processCytochrome P450 1B1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell population proliferationCytochrome P450 1B1Homo sapiens (human)
male gonad developmentCytochrome P450 1B1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressCytochrome P450 1B1Homo sapiens (human)
toxin metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionCytochrome P450 1B1Homo sapiens (human)
positive regulation of smooth muscle cell migrationCytochrome P450 1B1Homo sapiens (human)
sterol metabolic processCytochrome P450 1B1Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 1B1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
collagen fibril organizationCytochrome P450 1B1Homo sapiens (human)
adrenal gland developmentCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell migrationCytochrome P450 1B1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityCytochrome P450 1B1Homo sapiens (human)
response to follicle-stimulating hormoneCytochrome P450 1B1Homo sapiens (human)
response to estradiolCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinCytochrome P450 1B1Homo sapiens (human)
benzene-containing compound metabolic processCytochrome P450 1B1Homo sapiens (human)
retinol metabolic processCytochrome P450 1B1Homo sapiens (human)
retinal metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of apoptotic processCytochrome P450 1B1Homo sapiens (human)
blood vessel endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
estrous cycleCytochrome P450 1B1Homo sapiens (human)
positive regulation of translationCytochrome P450 1B1Homo sapiens (human)
positive regulation of angiogenesisCytochrome P450 1B1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCytochrome P450 1B1Homo sapiens (human)
membrane lipid catabolic processCytochrome P450 1B1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1B1Homo sapiens (human)
blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
retinal blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
ganglion developmentCytochrome P450 1B1Homo sapiens (human)
cellular response to hydrogen peroxideCytochrome P450 1B1Homo sapiens (human)
cellular response to cAMPCytochrome P450 1B1Homo sapiens (human)
cellular response to tumor necrosis factorCytochrome P450 1B1Homo sapiens (human)
cellular response to luteinizing hormone stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to cortisol stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to progesterone stimulusCytochrome P450 1B1Homo sapiens (human)
response to dexamethasoneCytochrome P450 1B1Homo sapiens (human)
endothelial cell-cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to indole-3-methanolCytochrome P450 1B1Homo sapiens (human)
cellular response to toxic substanceCytochrome P450 1B1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1B1Homo sapiens (human)
regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of DNA biosynthetic processCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (52)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingThiopurine S-methyltransferaseHomo sapiens (human)
thiopurine S-methyltransferase activityThiopurine S-methyltransferaseHomo sapiens (human)
S-adenosyl-L-methionine bindingThiopurine S-methyltransferaseHomo sapiens (human)
succinate-semialdehyde dehydrogenase (NAD+) activitySuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
identical protein bindingSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
4-aminobutyrate transaminase activity4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
pyridoxal phosphate binding4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
succinate-semialdehyde dehydrogenase binding4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
4-aminobutyrate:2-oxoglutarate transaminase activity4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
identical protein binding4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
metal ion binding4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
(S)-3-amino-2-methylpropionate transaminase activity4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
iron-sulfur cluster binding4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
monooxygenase activityCytochrome P450 1B1Homo sapiens (human)
iron ion bindingCytochrome P450 1B1Homo sapiens (human)
protein bindingCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
heme bindingCytochrome P450 1B1Homo sapiens (human)
aromatase activityCytochrome P450 1B1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1B1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytosolThiopurine S-methyltransferaseHomo sapiens (human)
mitochondrionSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrial matrixSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
synapseSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrionSuccinate-semialdehyde dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrion4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
mitochondrial matrix4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
4-aminobutyrate transaminase complex4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
mitochondrion4-aminobutyrate aminotransferase, mitochondrialHomo sapiens (human)
mitochondrionCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1B1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (118)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID677013Inhibition of AChE activity in rat brain homogenate using acetylthiocholine as substrate by Ellman's method2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Synthesis and evaluation of novel 4-[(3H,3aH,6aH)-3-phenyl)-4,6-dioxo-2-phenyldihydro-2H-pyrrolo[3,4-d]isoxazol-5(3H,6H,6aH)-yl]benzoic acid derivatives as potent acetylcholinesterase inhibitors and anti-amnestic agents.
AID24264Ability to undergo in vitro ester hydrolysis in 80% human plasma ( pH of 7.4) at 37 degree Celsius expressed as half life of ethyl ester hydrolysis1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Esters of N,N-disubstituted 2-hydroxyacetamides as a novel highly biolabile prodrug type for carboxylic acid agents.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID213093Inhibition of purified human kidney thiopurine methyltransferase (TPMT)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Thiopurine methyltransferase: structure-activity relationships for benzoic acid inhibitors and thiophenol substrates.
AID1306443Inhibition of recombinant human CYP1B1 expressed in Escherichia coli DH5aplha cells assessed as O-deethylation of ethoxyresorufin in presence of NADPH measured after 2 mins by spectrofluorometric method2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.
AID1628080Inhibition of mushroom tyrosinase using L-tyrosine as substrate assessed as dopachrome formation preincubated for 10 mins followed by protein addition measured after 20 mins by microplate reader analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Discovery of a new type of scaffold for the creation of novel tyrosinase inhibitors.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID23254Partition coefficient (logP) (chloroform)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID23251Partition coefficient (logP)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID24263Ability to undergo in vitro ester hydrolysis in 80% human plasma ( pH of 7.4) at 37 degree Celsius expressed as half life of N,N-diethylglycolamide ester hydrolysis1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Esters of N,N-disubstituted 2-hydroxyacetamides as a novel highly biolabile prodrug type for carboxylic acid agents.
AID1306441Inhibition of recombinant human CYP1A1 expressed in Escherichia coli DH5aplha cells assessed as O-deethylation of ethoxyresorufin in presence of NADPH measured after 2 mins by spectrofluorometric method2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID228541Enzymatic activity was determined1984Journal of medicinal chemistry, Jan, Volume: 27, Issue:1
Parasite enzymes as potential targets for antiparasitic chemotherapy.
AID1203998Antiinflammatory activity against mouse MB49-I cells assessed as inhibition of IFN-gamma/TNFalpha-NO production pretreated at 10 uM after 24 hrs by Griess reaction relative to vehicle treated control2015European journal of medicinal chemistry, , Volume: 96Identification of an anti-inflammatory derivative with anti-cancer potential: The impact of each of its structural components on inflammatory responses in macrophages and bladder cancer cells.
AID1602081Antibacterial activity against Pseudomonas aeruginosa ATCC 15442 measured after overnight incubation2019European journal of medicinal chemistry, Mar-15, Volume: 166Design, synthesis and anti-bacterial studies of piperazine derivatives against drug resistant bacteria.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1146787Activity of dihydropteroate synthase (unknown origin) assessed as rate of compound incorporation on dihydropteroic acid analogues incubated for 5 hrs under argon atmosphere by fluorescence assay1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
P-Aminobenzoic acid derivatives. Mode of action and structure-activity relationships in a cell-free system (Escherichia coli).
AID23253Partition coefficient (logP) (carbon tetrachloride)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID555374Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 0.40 % after 24 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID23252Partition coefficient (logP) (benzene)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID28692Concentration of the drug in the kidney of rat1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1146780Hydrolytic dissociation constant, pKa of the compound in aqueous solution at 50 degC1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
P-Aminobenzoic acid derivatives. Mode of action and structure-activity relationships in a cell-free system (Escherichia coli).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID71069Concentration required to sustain growth of Escherichia coli HDU-78; 1-10 nM2002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
Development of a genetic selection for catalytic antibodies.
AID28731Partition coefficient (logD2.0)1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID23255Partition coefficient (logP) (ether)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID260087Inhibitory activity against SSADH2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives.
AID147482In vitro inhibitory activity against H1N9 strain of Influenza neuraminidase (membrane) at 7 mM concentration1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
AID28497log (1/C') was determined1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID29132pI50 was determined1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID274670Inhibition of ADCS2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Aminodeoxychorismate synthase inhibitors from one-bead one-compound combinatorial libraries: "staged" inhibitor design.
AID1602080Antibacterial activity against Escherichia coli ATCC 25922 measured after overnight incubation2019European journal of medicinal chemistry, Mar-15, Volume: 166Design, synthesis and anti-bacterial studies of piperazine derivatives against drug resistant bacteria.
AID1146777Lipophilic-hydrophilic balance, Rm of the compound by TLC analysis1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
P-Aminobenzoic acid derivatives. Mode of action and structure-activity relationships in a cell-free system (Escherichia coli).
AID1306442Inhibition of recombinant human CYP1B1 expressed in Escherichia coli DH5aplha cells assessed as O-deethylation of ethoxyresorufin in presence of NADPH at 100 uM measured after 2 mins by spectrofluorometric method2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.
AID146231Dissociation constant for HCV NS3 protease substrate binding site2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening.
AID1432732Inhibition of Schistosoma japonicum C-terminal His6-tagged GST expressed in Escherichia coli BL21(DE3) assessed as reduction in GSH transfer activity by measuring residual activity at 10 mM using GSH/CDNB co-substrate mixture preincubated for 10 mins foll2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Efficient synthesis of α-fluoromethylhistidine di-hydrochloride and demonstration of its efficacy as a glutathione S-transferase inhibitor.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID603957Octanol-water partition coefficient, log P of the compound2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
QSPR modeling of octanol/water partition coefficient for vitamins by optimal descriptors calculated with SMILES.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1306440Inhibition of recombinant human CYP1A1 expressed in Escherichia coli DH5aplha cells assessed as O-deethylation of ethoxyresorufin in presence of NADPH at 100 uM measured after 2 mins by spectrofluorometric method2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.
AID28691log LD50 was determined1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID444561Binding affinity to Bacillus anthracis DHPS expressed in Escherichia coli BL21 (DE3) after 30 mins by isothermal titration calorimetry2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Structural studies of pterin-based inhibitors of dihydropteroate synthase.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID28693Concentration of the drug in the liver of rat1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1203999Antiinflammatory activity against mouse MB49-I cells assessed as inhibition of IFN-gamma/TNFalpha-NO production pretreated at 50 uM after 24 hrs by Griess reaction relative to vehicle treated control2015European journal of medicinal chemistry, , Volume: 96Identification of an anti-inflammatory derivative with anti-cancer potential: The impact of each of its structural components on inflammatory responses in macrophages and bladder cancer cells.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID226477Hammett constant was determined1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods.
AID23256Partition coefficient (logP) (hexane)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1602079Antibacterial activity against Bacillus subtilis ATCC 6633 measured after overnight incubation2019European journal of medicinal chemistry, Mar-15, Volume: 166Design, synthesis and anti-bacterial studies of piperazine derivatives against drug resistant bacteria.
AID260086Inhibitory activity against GABAT2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives.
AID1602078Antibacterial activity against Staphylococcus aureus ATCC 6538 measured after overnight incubation2019European journal of medicinal chemistry, Mar-15, Volume: 166Design, synthesis and anti-bacterial studies of piperazine derivatives against drug resistant bacteria.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1060463Inhibition of Sir2p in yeast DMY2844 assessed as growth inhibition after 48 hrs2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Evaluation of benzoic acid derivatives as sirtuin inhibitors.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID226478Hammett constant was evaluated1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID555343Effect on growth in Staphylococcus aureus MN8 at 0.20 % after 24 hrs (Rvb = 100%)2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1146776Partition coefficient, log P of the compound1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
P-Aminobenzoic acid derivatives. Mode of action and structure-activity relationships in a cell-free system (Escherichia coli).
AID555342Effect on growth in Staphylococcus aureus MN8 at 0.40 % after 24 hrs (Rvb = 100%)2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID555375Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 0.20 % after 24 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2012Biochemistry, Feb-14, Volume: 51, Issue:6
Crystallographic analysis of active site contributions to regiospecificity in the diiron enzyme toluene 4-monooxygenase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,899)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901492 (51.47)18.7374
1990's413 (14.25)18.2507
2000's363 (12.52)29.6817
2010's491 (16.94)24.3611
2020's140 (4.83)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.76 (24.57)
Research Supply Index7.92 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index141.88 (26.88)
Search Engine Supply Index2.85 (0.95)

This Compound (56.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials55 (2.04%)5.53%
Trials60 (5.29%)5.53%
Reviews94 (3.48%)6.00%
Reviews43 (3.79%)6.00%
Case Studies64 (2.37%)4.05%
Case Studies31 (2.73%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other2,485 (92.11%)84.16%
Other1,000 (88.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]